Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
/ l/ E9 e- t- F' z* s3 u+ ^# B; |
' a2 l' w) `- H$ }7 i% Y7 Y9 I- l
Sub-category:
: |2 V& Y# _# M5 t; vMolecular Targets
) Q1 N0 T+ E) r' K8 Q M+ c/ ]- a7 b5 |2 X
: y6 u6 S+ L' T8 {8 D& V
Category: M) z; W, S6 O" a. `( s
Tumor Biology
0 A3 O- q. u% i8 `% B# N( N
9 E- J( f- N6 f& z
3 L" N) I1 \% i0 \Meeting: n+ _% L3 n1 C( Z: M
2011 ASCO Annual Meeting
+ `$ g3 a/ U" K5 @, l$ [( E7 W' u3 k9 u H* e7 c! @9 o7 O: i1 l
/ R2 g8 q1 K8 M- ySession Type and Session Title:% O- ^* O' [( {2 w/ n
Poster Discussion Session, Tumor Biology
2 d$ p! N: T. z5 Q: N# t' C$ j& |1 ^& S
# W; |) Z K4 B, N6 NAbstract No:
2 E/ L6 j# }6 l% f# ?8 V10517
9 {5 r9 d+ ?& s$ h! c- [
5 D7 x+ h* n) E3 }9 d! u/ `% G6 }( x. p- p$ }+ t" x
Citation:
7 o2 a7 M1 f1 N$ e1 \J Clin Oncol 29: 2011 (suppl; abstr 10517) , X! I& m8 V$ h" k u3 U' z5 H: J
5 L2 Z- ?* k6 P9 ^5 p/ A: p
; B, O6 j0 j1 U$ d
Author(s):
3 _# ?$ p* u. C g+ n7 X5 `& pJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China $ s% c4 K' ^# n! c. d
! K% s" ]/ O6 w( w( o6 z* m( f
$ o6 C8 ~% l* q: w* s4 R& m, J# `
' }5 F+ A; ? _. M+ v) JAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.7 R9 I6 p5 o+ m- I: `9 }
9 U- p3 \& g- E v3 Q
Abstract Disclosures
[. |: M! [9 p( H8 a3 O# f
* m e' m5 D4 L! w3 G; }Abstract:
0 W/ h# i+ e/ z( w7 S2 [$ z
5 n. H1 a6 ^6 m* @8 t5 K! O" Q6 S5 `! t- d4 }
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
# g. }+ H- i/ B1 q. b9 ]8 @6 S' X# w1 X+ S$ v0 ^' e+ G
$ l- `" w: f( j" v |